Composition, pharmaceutical composition, use of a stable topical composition comprising a nanoemulsion and of at least one antileishmanial compound, and method for the treatment of cutaneous leishmaniasis
US-2024016826-A1 · Jan 18, 2024 · US
Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way
US8945922B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8945922-B2 |
| Application number | US-200913062453-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2009 |
| Priority date | Sep 8, 2008 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell having TCRα rearranged to NKT-TCR (NKT-iPS cell), obtained by contacting a somatic cell, such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, with nuclear reprogramming factors, isolated NKT cells obtained by differentiating the iPS cell ex vivo (iPS-NKT cell), a method of generating CD4/CD8-double positive NKT cells (DP-NKT cells) and mature NKT cells from NKT-iPS cells by altering the combination of feeder cells and/or cytokines, a method of expanding the iPS-NKT cells, and an NKT cell cytotherapy agent comprising NKT cells activated with α-galactosyl ceramide (α-GalCer), or iPS-NKT cells, and α-GalCer in combination.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of generating a mature NKT cell, comprising (a) providing a CD4/CD8-double positive NKT cell, wherein the CD4/CD8-double positive NKT cell was obtained by co-culturing a cloned cell with a stromal cell that expresses a Notch ligand as a feeder cell in the presence of interleukin-7 and Flt3 ligand, and wherein the cloned cell has been obtained by (i) transducing a somatic cell having the α-chain region of the T cell antigen receptor gene rearr…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8945922B2 cover?
- Provided are an iPS cell derived from a somatic cell such as an NKT cell, having the α-chain region of the T cell antigen receptor gene rearranged to uniform Vα-Jα in an NKT cell receptor-specific way, NKT cells differentiated from the iPS cell, a method of creating the same, and an immune cell therapy agent prepared using cells differentiated from the iPS cell. Also provided are an iPS cell ha…
- Who is the assignee on this patent?
- Watarai Hiroshi, Koseki Haruhiko, Taniguchi Masaru, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7036. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).